BioNTech Non Current Assets Total vs Cash And Short Term Investments Analysis
BNTX Stock | USD 94.10 2.85 2.94% |
BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Non Current Assets Total and its Cash And Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
Non Current Assets Total vs Cash And Short Term Investments
Non Current Assets Total vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Non Current Assets Total account and Cash And Short Term Investments. At this time, the significance of the direction appears to have almost identical trend.
The correlation between BioNTech's Non Current Assets Total and Cash And Short Term Investments is 0.94. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Non Current Assets Total and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of BioNTech SE are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Non Current Assets Total i.e., BioNTech's Non Current Assets Total and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.94 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of BioNTech SE balance sheet. This account contains BioNTech investments that will expire within one year. These investments include stocks and bonds that can be liquidated by BioNTech SE fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.
BioNTech fundamental ratios Correlations
Click cells to compare fundamentals
BioNTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioNTech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 24.2B | |
Short Long Term Debt Total | 68.9M | 240.2M | 301.5M | 212.2M | 219.1M | 161.3M | |
Other Current Liab | 16.4M | 103.1M | 3.0B | 2.6B | 1.3B | 979.8M | |
Total Current Liabilities | 138.1M | 606.0M | 3.5B | 3.0B | 2.1B | 1.3B | |
Total Stockholder Equity | 493.5M | 1.4B | 11.9B | 20.1B | 20.2B | 21.3B | |
Other Liab | 205.6M | 97.1M | 109.7M | 283.9M | 326.5M | 166.9M | |
Net Tangible Assets | 179.6M | 406.5M | 1.2B | 11.7B | 13.5B | 14.1B | |
Property Plant And Equipment Net | 148.1M | 326.0M | 520.4M | 821.1M | 971.6M | 1.0B | |
Current Deferred Revenue | 93.6M | 391.5M | 189.1M | 77.1M | 353.3M | 371.0M | |
Net Debt | (450.2M) | (970.0M) | (1.4B) | (13.7B) | (11.4B) | (10.9B) | |
Retained Earnings | (424.8M) | (409.6M) | 9.9B | 18.8B | 19.8B | 20.8B | |
Accounts Payable | 20.5M | 102.3M | 160M | 204.1M | 354M | 371.7M | |
Cash | 519.1M | 1.2B | 1.7B | 13.9B | 11.7B | 12.2B | |
Non Current Assets Total | 237.5M | 651.7M | 758.5M | 1.4B | 3.5B | 3.7B | |
Non Currrent Assets Other | 2K | 1.0M | 800K | 6.5M | 83.4M | 87.6M | |
Other Assets | 2.4M | 168.2M | 22.2M | 249.2M | 286.6M | 300.9M | |
Long Term Debt | 68.9M | 231.0M | 171.6M | 176.2M | 191M | 116.1M | |
Cash And Short Term Investments | 520.8M | 1.3B | 2.1B | 14.1B | 16.5B | 17.4B | |
Net Receivables | 20.2M | 166.4M | 12.4B | 7.1B | 2.3B | 3.0B | |
Good Will | 3.0M | 53.7M | 57.8M | 61.2M | 362.5M | 380.6M | |
Common Stock Total Equity | 166.8M | 193.3M | 232.3M | 246.3M | 283.3M | 185.2M | |
Common Stock Shares Outstanding | 211.5M | 248.5M | 259.7M | 249.8M | 242.7M | 229.1M | |
Short Term Investments | 1.7M | 137.2M | 381.6M | 189.4M | 4.9B | 5.1B | |
Liabilities And Stockholders Equity | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 24.2B | |
Non Current Liabilities Total | 166.0M | 340.8M | 455.5M | 272.9M | 689.9M | 378.2M | |
Inventory | 11.7M | 64.1M | 502.5M | 439.6M | 357.7M | 190.9M | |
Other Current Assets | 1.2M | 61.0M | 64.9M | 271.9M | 280.9M | 294.9M | |
Other Stockholder Equity | (5.5M) | 1.5B | (3.8M) | (5.3M) | 1.2B | 1.3B | |
Total Liab | 304.2M | 946.8M | 3.9B | 3.2B | 2.8B | 1.7B | |
Property Plant And Equipment Gross | 148.1M | 326.0M | 594.6M | 821.1M | 1.2B | 1.2B | |
Total Current Assets | 560.2M | 1.7B | 15.1B | 21.9B | 19.5B | 20.5B | |
Accumulated Other Comprehensive Income | 691.5M | 25.5M | 1.8B | 979.3M | (984.6M) | (935.4M) | |
Short Term Debt | 7.6M | 9.1M | 129.9M | 36M | 28.1M | 32.9M | |
Intangible Assets | 86.5M | 109.8M | 144.6M | 158.5M | 804.1M | 844.3M | |
Common Stock | 232.3M | 246.3M | 246.3M | 248.6M | 285.9M | 218.0M | |
Property Plant Equipment | 116.0M | 148.1M | 326.0M | 520.4M | 598.5M | 628.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 0.5 | Revenue Per Share 11.369 | Quarterly Revenue Growth (0.85) | Return On Assets (0.01) |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.